In re Adolor Corp. Sec. Litig., 2009 U.S. Dist. LEXIS 40045

In a securities fraud case against a drug company, the complaint's allegations regarding the company's statements that drug trials were randomized and double-blinded amounted to disagreements over the proper methodology and conduct of clinical studies and were not sufficient to establish falsity for purposes of a Rule 10b-5 claim.
 
Lexis.com subscribers can view the enhanced version of In re Adolor Corp. Sec. Litig.